EC Ophthalmology

Mini Review Volume 14 Issue 4 - 2023

Association of Alzheimer’s Disease, Chronic Glaucoma and Age-Related Macular Degeneration

Alexandros Tsilis1* and Sygkliti-Henrietta Pelidou2

1Faculty of Medicine, University of Ioannina, Ioannina, Greece
2Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece

*Corresponding Author: Alexandros Tsilis, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
Received: March 01, 2023; Published: March 20, 2023

Recent evidence has suggested a potential association between Alzheimer’s disease (AD), chronic glaucoma (CGL) and age-related macular degeneration (AMD). Although several lines of evidence indicate that CGL and AMD may be associated with AD due to common pathophysiological mechanisms including progressive neurodegeneration, characteristic amyloid-β (Aβ) deposits and chronic microvascular insults, there is still no definite answer. Therefore, we conducted a mini-review to describe the findings of the AD, CGL and AMD literature. Further research, including large and well-designed prospective studies with long follow-ups, is needed to clarify this association.

Keywords: Neurodegenerative Diseases; Alzheimer’s Disease; Chronic Glaucoma; Age-Related Macular Degeneration

  1. Lee CS., et al. “Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease”. Alzheimer's and Dementia Journal1 (2019): 34-41.
  2. London A., et al. “The retina as a window to the brain-from eye research to CNS disorders”. Nature Reviews Neurology1 (2013): 44-53.
  3. Tsilis AG., et al. “Systematic review of the association between Alzheimer's disease and chronic glaucoma”. Clinical Ophthalmology 8 (2014): 2095-2104.
  4. Mancino R., et al. “Glaucoma and Alzheimer Disease: One Age-Related Neurodegenerative Disease of the Brain”. Current Neuropharmacology7 (2018): 971-977.
  5. Reitz C., et al. “Epidemiology of Alzheimer disease”. Nature Reviews Neurology3 (2011): 137-152.
  6. Alzheimer’s Association. “2015 Alzheimer's disease facts and figures”. Alzheimer's and Dementia3 (2015): 332-384.
  7. Querfurth HW., et al. “Alzheimer's disease”. The New England Journal of Medicine4 (2010): 329-344.
  8. Harris FM., et al. “Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice”. Proceedings of the National Academy of Sciences of the United States of America19 (2003): 10966-10971.
  9. Selkoe DJ. “The molecular pathology of Alzheimer's disease”. Neuron4 (1991): 487-498.
  10. Tanzi RE., et al. “New frontiers in Alzheimer's disease genetics”. Neuron2 (2001): 181-184.
  11. Sivak JM. “The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease”. Investigative Ophthalmology and Visual Science1 (2013): 871-880.
  12. Weinreb RN., et al. “The pathophysiology and treatment of glaucoma: a review”. The Journal of the American Medical Association18 (2014): 1901-1911.
  13. Nucci C., et al. “Neuroprotective agents in the management of glaucoma”. Eye5 (2018): 938-945.
  14. Nickells RW., et al. “Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy”. Annual Review of Neuroscience 35 (2012): 153-179.
  15. Quigley HA., et al. “The number of people with glaucoma worldwide in 2010 and 2020”. British Journal of Ophthalmology3 (2006): 262-267.
  16. Klein R., et al. “Prevalence of age-related maculopathy. The Beaver Dam Eye Study”. Ophthalmology6 (1992): 933-943.
  17. Friedman DS., et al. “Prevalence of age-related macular degeneration in the United States”. Archives of Ophthalmology4 (2004): 564-572.
  18. Kaarniranta K., et al. “Age-related macular degeneration (AMD): Alzheimer's disease in the eye?” Journal of Alzheimer's Disease4 (2011): 615-631.
  19. Chandra V., et al. “Conditions associated with Alzheimer's disease at death: case-control study”. Neurology2 (1986): 209-211.
  20. Bayer AU., et al. “Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease”. American Journal of Ophthalmology1 (2002): 135-137.
  21. Bayer AU., et al. “High occurrence rate of glaucoma among patients with Alzheimer's disease”. European Neurology3 (2002): 165-168.
  22. Tamura H., et al. “High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease”. Journal of the Neurological Sciences1-2 (2006): 79-83.
  23. Ou Y., et al. “Glaucoma, Alzheimer disease and other dementia: a longitudinal analysis”. Ophthalmic Epidemiology5 (2012): 285-292.
  24. Blanks JC., et al. “Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina”. Neurobiology of Aging3 (1996): 377-384.
  25. Parisi V., et al. “Morphological and functional retinal impairment in Alzheimer's disease patients”. Clinical Neurophysiology10 (2001): 1860-1867.
  26. Iseri PK., et al. “Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease”. Journal of Neuro-Ophthalmology1 (2006): 18-24.
  27. Gupta N., et al. “Retinal tau pathology in human glaucomas”. Canadian Ophthalmological Society1 (2008): 53-60.
  28. Yoneda S., et al. “Vitreous fluid levels of beta-amyloid ((1-42)) and tau in patients with retinal diseases”. The Japanese Journal of Ophthalmology2 (2005): 106-108.
  29. McKinnon SJ., et al. “Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension”. Investigative Ophthalmology and Visual Science4 (2002): 1077-1087.
  30. Guo L., et al. “Targeting amyloid-beta in glaucoma treatment”. Proceedings of the National Academy of Sciences of the United States of America33 (2007): 13444-13449.
  31. Ning A., et al. “Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease”. Investigative Ophthalmology and Visual Science11 (2008): 5136-5143.
  32. Liu B., et al. “Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice”. The American Journal of Pathology5 (2009): 2099-2110.
  33. Perez SE., et al. “Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease”. Investigative Ophthalmology and Visual Science2 (2009): 793-800.
  34. Gasparini L., et al. “Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability”. Neurobiology of Aging3 (2011): 419-433.
  35. Keenan TD., et al. “Associations between age-related macular degeneration, Alzheimer disease, and dementia: record linkage study of hospital admissions”. JAMA Ophthalmology1 (2014): 63-68.
  36. Klaver CC., et al. “Is age-related maculopathy associated with Alzheimer's Disease? The Rotterdam Study”. American Journal of Epidemiology9 (1999): 963-968.
  37. Wong TY., et al. “Is early age-related maculopathy related to cognitive function? The Atherosclerosis Risk in Communities Study”. American Journal of Ophthalmology6 (2002): 828-835.
  38. Pham TQ., et al. “Relation of age-related macular degeneration and cognitive impairment in an older population”. Gerontology6 (2006): 353-358.
  39. Woo SJ., et al. “Cognitive impairment in age-related macular degeneration and geographic atrophy”. Ophthalmology10 (2012): 2094-2101.
  40. Baker ML., et al. “Early age-related macular degeneration, cognitive function, and dementia: the Cardiovascular Health Study”. Archives of Ophthalmology5 (2009): 667-673.
  41. Wen LY., et al. “Increased risk of Alzheimer's disease among patients with age-related macular degeneration: A nationwide population-based study”. PLoS One5 (2021): e0250440.
  42. Johnson LV., et al. “The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration”. Proceedings of the National Academy of Sciences of the United States of America18 (2002): 11830-11835.
  43. Dentchev T., et al. “Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas”. Molecular Vision 9 (2003): 184-190.
  44. Anderson DH., et al. “Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration”. Experimental Eye Research2 (2004): 243-256.
  45. Luibl V., et al. “Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers”. Journal of Clinical Investigation2 (2006): 378-385.
  46. Löffler KU., et al. “Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina”. Investigative Ophthalmology and Visual Science1 (1995): 24-31.
  47. Yoshida T., et al. “The potential role of amyloid beta in the pathogenesis of age-related macular degeneration”. Journal of Clinical Investigation10 (2005): 2793-2800.
  48. Isas JM., et al. “Soluble and mature amyloid fibrils in drusen deposits”. Investigative Ophthalmology and Visual Science3 (2010): 1304-1310.
  49. Bruban J., et al. “Amyloid-beta (1-42) alters structure and function of retinal pigmented epithelial cells”. Aging Cell2 (2009): 162-177.
  50. Schwaber EJ., et al. “Co-Prevalence of Alzheimer's Disease and Age-Related Macular Degeneration Established by Histopathologic Diagnosis”. Journal of Alzheimer's Disease1 (2020): 207-215.

Alexandros Tsilis and Sygkliti-Henrietta Pelidou. Association of Alzheimer’s Disease, Chronic Glaucoma and Age-Related Macular Degeneration. EC Ophthalmology 14.4 (2023): 08-14.